Ozempic and GLP-1 Drugs: How They Actually Work

For the first time, medicine has drugs that reliably produce major weight loss. That sentence deserves both its weight and its fine print. Here is the mechanism, the numbers, the costs, and the parts the ads leave out.

The mechanism, in one paragraph#

After you eat, the gut releases a hormone called GLP-1. It tells the pancreas to release insulin, slows the stomach so the meal lingers, and tells the brain's appetite centers that you are done. The drugs, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are long-acting copies of that signal, injected weekly. The effect people report is not willpower; it is silence. The constant background negotiation with food, what patients call food noise, largely stops.

The numbers#

In trials, semaglutide produced roughly 15 percent body weight loss over 68 weeks; tirzepatide passed 20 percent at the top dose. Nothing prescribable before them came close. In people with existing heart disease and obesity, semaglutide also cut heart attacks and strokes by a fifth, which is why cardiologists now care about a weight drug.

The other number: in stop trials, most of the weight returned within a year of the last dose. These drugs manage a biology; they do not reset it.

What it costs the body#

Early gut effects, nausea, constipation, reflux, are common and usually fade with slow dose increases. The quieter cost is lean mass: fast weight loss takes muscle along with fat, and in older adults that muscle is the difference between aging and frailty. The counter-measures are the same two things this site never stops saying: protein at every meal, checked against your real target, and two strength sessions a week. Rare but serious: pancreatitis, gallbladder disease. And the compounded knock-offs sold online have put people in hospitals through dosing errors; the savings are not worth the syringe.

The honest framing#

These are chronic-condition drugs, like blood pressure tablets: they work while taken, at real cost, for people whose weight already threatens their health. For that group the trials justify them. For someone with fifteen stubborn pounds and a functioning routine, the free levers still do the job without the invoice or the nausea.

If you are weighing this decision, our doctors answer written questions about what the evidence means for a situation like yours, and the Health Review reads your numbers before you and your own doctor decide anything.